Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 9/20 | 1.00 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22812895 | 1.00 | APLNR (1.00) | APLNRCCR1CCR5CCR8HDAC6 | |
| SCHEMBL18246523 | 1.00 | APLNR (1.00) | APLNRCCR1CCR5CCR8HDAC6 | |
| SCHEMBL18474514 | 1.00 | APLNR (1.00) | APLNRCCR1CCR5CCR8HDAC6 | |
| SCHEMBL18246176 | 1.00 | APLNR (1.00) | APLNRCCR1CCR5CCR8HDAC6 | |
| SCHEMBL18246399 | 1.00 | APLNR (1.00) | APLNRCCR1CCR5CCR8HDAC6 | |
| SCHEMBL20201096 | 0.86 | APLNR (0.75) | APLNRCCR1CCR5CCR8HDAC6 | |
| SCHEMBL20201097 | 0.86 | APLNR (0.75) | APLNRCCR1CCR5CCR8HDAC6 | |
| SCHEMBL20180743 | 0.81 | APLNR (0.68) | APLNRCCR1CCR5CCR8HDAC6 | |
| SCHEMBL12457569 | 0.80 | APLNR (0.67) | APLNRCCR1CCR5CCR8HDAC6 | |
| SCHEMBL27463869 | 0.80 | APLNR (0.67) | APLNRCCR1CCR5CCR8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541804-B1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2025-01-22 | — | — | EP | disclosed |
| EP-3541802-B1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2025-01-01 | — | — | EP | disclosed |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11191762-B2 | Alkyl substituted triazole compounds as agonists of the APJ Receptor | AMGEN INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-11149040-B2 | Fused triazole agonists of the APJ receptor | AMGEN INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210246118-A1 | SUBSTITUTED PYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2021-08-12 | — | — | US | disclosed |
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AMGEN INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11020395-B2 | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-10906890-B2 | Triazole phenyl compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2021-02-02 | — | — | US | disclosed |
| EP-3300500-B9 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2021-01-13 | — | — | EP | disclosed |
| WO-2018097944-A1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018093577-A1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093576-A1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093579-A1 | TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093579-A1 | TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093580-A1 | TRIAZOLE PYRIDYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093580-A1 | TRIAZOLE PYRIDYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2017192485-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| US-20170320860-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-11-09 | — | — | US | disclosed |
| WO-2017192485-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2017-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AGTR1, AGTR2, TBXA2R | APLNR 13/4885CCR1 2951/4885CCR5 1138/4885 |
| US-11191762-B2 | Alkyl substituted triazole compounds as agonists of the APJ Receptor | AGTR1, AGTR2, APLNR | APLNR 3/4885CCR1 1991/4885CCR5 850/4885 |
| US-11020395-B2 | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor | AGTR1, AGTR2, TBXA2R | APLNR 4/4885CCR1 1106/4885CCR5 443/4885 |
| US-10906890-B2 | Triazole phenyl compounds as agonists of the APJ receptor | AGTR1, AGTR2, TBXA2R | APLNR 4/4885CCR1 2250/4885CCR5 1194/4885 |
| US-20210246118-A1 | SUBSTITUTED PYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR | APLNR, AGTR1, AGTR2 | APLNR 1/4885CCR1 1305/4885CCR5 242/4885 |
| US-11149040-B2 | Fused triazole agonists of the APJ receptor | TBXA2R, AP3M1, GPBAR1 | APLNR 5/4885CCR1 3324/4885CCR5 1858/4885 |
| US-20170320860-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | TBXA2R, APLNR, AGTR1 | APLNR 2/4885CCR1 2159/4885CCR5 852/4885 |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | APLNR, AGTR1, AGTR2 | APLNR 1/4885CCR1 1305/4885CCR5 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.